Pharmaceuticals, Biotechnology and Life Sciences
NanoViricides confirmed in a statement that its CEO, Dr. Irach Taraporewala has resigned effective January 31, 2019, for personal reasons, and will continue as a Consultant to help the company with its regulatory advance as needed. The Board has promoted current President and Board Chairman, Dr. Anil Diwan, to Executive Chairman.
Read more
Innate Pharma will speed up the development of its anti-KIR3DL2 antibody, to treat T-cell lymphoma, as it has been fast tracked by the US FDA, the company said Tuesday.
Read more
Patients with certain plaque psoriasis treated with 300mg of Cosentyx for only four weeks reported in a questionnaire improvements in life quality, novartis said Monday.
Read more
U.S. Food and Drug Administration (FDA) approved AbbVie’s Imruvica (ibrutinib) combined rituximab (Rituxan) for treating adult patients with Waldenström’s macroglobulinemia (WM).
Read more
Destiny Pharma’s XF-73 nasal gel formulation has been classified non-irritant, in the second Phase 1 study, which confirms the good safety profile.
Read moreTheravance Biopharma has started dosing patients with symptomatic neurogenic orthostatic hypotension (nOH) to test its investigational neropinephrine reuptake inhibitor ampreloxetine (TD-9855), in a registrational Phase 3 clinical trial
Read more
Amgen’s Repatha will now be used as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Read more
Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech to discover new small molecule-based therapeutics utilizing Philochem’s novel lead-generation technologies.
Read more
The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical and clinical trials industries, has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.
Read more
In line with KRAIBURG TPE’s 2019 strategy to increase its focus on medical applications and pharmaceutical packaging, the company recently collaborated with Eastman to develop a range of innovative high-purity TPEs. In close cooperation with Eastman, KRAIBURG TPE has developed a range of THERMOLAST® M thermoplastic elastomers (TPEs) with the capability to adhere directly to specialized polymers used in medical applications, including Eastman’s Tritan™ copolyester, PP, ABS, ABS/PC, and PET.
Read more